Is Cladribine in shortage in 2026? Get the latest on Mavenclad availability, why access is limited, what it costs, and how to find it in stock near you.
If you've been searching for Cladribine and coming up empty, you might be wondering: is there a shortage? The answer is nuanced. While Cladribine (brand name Mavenclad) isn't on the FDA's official drug shortage list as of early 2026, many patients experience real delays and difficulty getting their prescriptions filled.
Here's what's actually going on — and what you can do about it.
Technically, Mavenclad (oral Cladribine tablets) is not in a formal FDA shortage as of March 2026. The brand-name product from EMD Serono is being manufactured and distributed through specialty pharmacies.
However, the injectable form of Cladribine (sold as Leustatin and as generics for hairy cell leukemia) has had a history of intermittent supply disruptions dating back to the mid-2010s. These shortages are related to limited manufacturers and the relatively small patient population for hairy cell leukemia.
For MS patients, the access challenges with Mavenclad are less about manufacturing shortages and more about the specialty pharmacy distribution system, insurance requirements, and coordination delays.
Even without a formal shortage, several factors make Cladribine difficult to access in 2026:
Mavenclad is only available through specialty pharmacies — not your local retail pharmacy. These pharmacies require prescriber enrollment, patient intake forms, and often coordinate directly with insurance. This adds days or weeks to the process.
Nearly all insurance plans require prior authorization for Cladribine. Many also mandate step therapy, meaning you must try and fail on at least one or two other MS medications first. If documentation is incomplete, authorizations are denied, creating further delays.
Cladribine is primarily prescribed by MS-specialist neurologists. If you're in a rural area or don't have easy access to an MS center, getting prescribed Cladribine in the first place may be the biggest hurdle. For help, see our guide on finding a doctor who can prescribe Cladribine.
At a list price of approximately $99,500 per annual treatment course, Cladribine triggers heightened review from insurance companies, pharmacy benefit managers, and specialty pharmacies — all of which slow down the process.
Here's a breakdown of current pricing:
For detailed savings strategies, visit our complete guide to saving money on Cladribine.
The biggest development for Cladribine access is the FDA approval of generic Cladribine tablets in November 2025. Manufactured by Apotex Inc., this generic has the potential to improve supply, increase competition, and — over time — reduce costs. It's still early days for distribution, but patients should ask their specialty pharmacy about generic availability.
Tools like Medfinder are making it easier for patients to locate medications in stock, cutting down on the phone calls and uncertainty. If you're struggling to find Cladribine, Medfinder can show you which pharmacies have it available.
Here's a step-by-step approach:
For more detailed strategies, read our full guide on how to find Cladribine in stock near you.
Cladribine isn't technically in shortage — but for many patients, it sure feels like it. The combination of specialty pharmacy distribution, insurance barriers, limited prescribers, and high cost creates a real access gap. The good news is that the 2025 generic approval, manufacturer support programs, and new patient tools are making things better.
If you're waiting on Cladribine, don't wait in silence. Use the resources above, stay in close contact with your doctor's office, and remember that you have the right to appeal insurance denials. Your MS treatment matters, and there are people and tools ready to help you access it.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
